Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) (“Enumeral” or the “Company”), a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today announced that Arthur H. Tinkelenberg, Ph.D., Enumeral’s President and Chief Executive Officer, will participate in the 2016 East/West CEO Conference on the panel entitled “Academia and Industry: Challenges and Synergies,” on Sunday, January 10, 2016 at 1:30 p.m. Pacific Time. The conference will be held at the Four Seasons Hotel in San Francisco, CA.

About Enumeral

Enumeral is a biopharmaceutical company discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases. The Company is building a pipeline focused on next-generation checkpoint modulators, with initial targets including PD-1, TIM-3, LAG-3, TIGIT, VISTA, and others. In developing these agents, Enumeral’s researchers apply a proprietary immune profiling technology platform that measures functioning of the human immune system at the level of individual cells, providing key insights for candidate selection and validation. For more information on Enumeral, please visit www.enumeral.com.